Mayo Clinic CEO announces retirement after nearly a decade at the helm

By Catherine Sturman
Share
President and CEO of Mayo Clinic, Dr John Noseworthy has announced his plans to retire at the end of 2018 after nine years leading the research group...

President and CEO of Mayo Clinic, Dr John Noseworthy has announced his plans to retire at the end of 2018 after nine years leading the research group’s operations and 28 years at the Clinic.

The clinic’s reputation has soared under Dr Noseworthy’s leadership, where it has seen one of the its strongest years with regards to quality and safety, research advancements and clinical practice. It has also completed its $3.76bn, eight-year philanthropic campaign.

“2017 was an extraordinary year for Mayo Clinic, and I look forward to working with our leadership team throughout 2018 to continue to strengthen Mayo Clinic and advance our humanitarian mission,” said Dr Noseworthy.

Mayo’s 2017 annual report, highlights that it has gained over $700mn in income, with a 49% increase in net income from 2016. The clinic has also undergone a significant recruitment drive.

See also

“Dr. Noseworthy’s inspirational and compassionate leadership has guided the organisation from a group of separate clinics and hospitals to a single integrated organisation focused on serving our patients,” added Jeff Bolton, Vice President, Administration, Mayo Clinic.

Samuel Di Piazza, Chair, Mayo Clinic Board of Trustees commented, “During his tenure as CEO, Dr. Noseworthy led Mayo Clinic to focus on key priorities, significantly increase its external visibility and achieve designation as the No. 1 hospital in the nation by U.S. News & World Report in 2016 and 2017.

“Mayo Clinic has consistently advanced its strategic direction under Dr. Noseworthy’s leadership and is well-positioned for continued success in 2018.”

Its new CEO will be announced in August once identified and transition plans are put in place.

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma